This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally
The Big Market Report Take
This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.
Not financial advice. The Big Market Report aggregates news for informational purposes only. Nothing on this site constitutes investment advice. Equities and other securities are subject to market risk. Always do your own research and consult a qualified financial advisor before making any investment decisions. Full disclaimer →
Never miss a story
More from this section
- UnitedHealth: Stabilizing, But Not Yet A BuySeeking Alpha22m ago
2 Top Cybersecurity Stocks to Buy in MarchThe Motley Fool29m ago- Zeta Gains Far More Appeal With Marigold PurchaseSeeking Alpha30m ago
OpenSea postpones SEA token launch, citing ‘challenging’ conditionsCoinTelegraph33m ago- Fed Officials Face Diverging MandatesSeeking Alpha44m ago